<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00212056</url>
  </required_header>
  <id_info>
    <org_study_id>CSSCJ-1</org_study_id>
    <secondary_id>UMIN_ID:C000000088</secondary_id>
    <nct_id>NCT00212056</nct_id>
  </id_info>
  <brief_title>Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP</brief_title>
  <official_title>Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cerebral and Cardiovascular Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Cardiovascular Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cerebral and Cardiovascular Center</source>
  <brief_summary>
    <textblock>
      To evaluate whether ANP as an adjunctive therapy for AMI reduces myocardial infarct size and
      improves regional wall motion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The benefits of percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI)
      are limited by reperfusion injury. In animal models, atrial natriuretic peptide (ANP) reduces
      infarct size, so the Japan-Working groups of acute myocardial Infarction for the reduction of
      Necrotic Damage by ANP(J-WINDANP) designed a prospective, randomized, multicenter study, to
      evaluate whether ANP as an adjunctive therapy for AMI reduces myocardial infarct size and
      improves regional wall motion.

      Twenty hospitals in Japan will participate in the J-WIND-ANP study. Patients with AMI who are
      candidates for PCI are randomly allocated to receive either intravenous ANP or placebo
      administration. The primary end-points are (1) estimated infarct size (Σcreatine kinase and
      troponin T) and (2) left ventricular function (left ventriculograms). Single nucleotide
      polymorphisms (SNPs) that may be associated with the function of ANP and susceptibility of
      AMI will be examined. Furthermore, a data mining method will be used to design the optimal
      combinational therapy for post-MI patients.

      J-WIND-ANP will provide important data on the effects of ANP as an adjunct to PCI for AMI and
      the SNPs information will open the field of tailor-made therapy. The optimal therapeutic drug
      combination will also be determined for post-MI patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>estimated infarct size</measure>
    <time_frame>72hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>left ventricular function (left ventricular ejection fraction and end-diastolic volume) and regional wall motion</measure>
    <time_frame>2-8weeks and 6-12months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival rate</measure>
    <time_frame>2.7years (median follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular events (ie, cardiac death, nonfatal re-infarction, re-hospitalization because of cardiac disease, revascularization)</measure>
    <time_frame>2.7years (median follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reperfusion injury (ie, malignant ventricular arrhythmia during reperfusion periods, re-elevation of ST-segment, worsening of chest pain)</measure>
    <time_frame>24hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the association of SNPs of ANP-related genes with response to ANP treatment</measure>
    <time_frame>2.7years (median follow-up)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>ANP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANP(hANP)</intervention_name>
    <description>0∙025 μg/kg per min for 3 days(intravenous)</description>
    <arm_group_label>ANP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 20-79 years

          2. Chest pain of more than 30 min

          3. 0.1 mV ST-segment elevation in 2 contiguous ECG leads

          4. Admission to hospital within 12 h of symptom onset

          5. First episode of AMI

          6. Candidates for PCI

        Exclusion Criteria:

          1. History of old myocardial infarction

          2. Left main coronary artery stenosis

          3. Severe liver and/or kidney dysfunction

          4. Suspected aortic dissection

          5. History of coronary artery bypass graft

          6. History of allergic response to drugs

          7. Severe hypovolemia

          8. Right ventricular infarction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masafumi Kitakaze, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cerebral and Cardiovascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>544-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Minamino T, Jiyoong K, Asakura M, Shintani Y, Asanuma H, Kitakaze M; J-WIND Investigators. Rationale and design of a large-scale trial using nicorandil as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by a K-ATP channel opener (J-WIND-KATP). Circ J. 2004 Feb;68(2):101-6.</citation>
    <PMID>14745142</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>October 31, 2007</last_update_submitted>
  <last_update_submitted_qc>October 31, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2007</last_update_posted>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Atrial natriuretic peptide</keyword>
  <keyword>Data mining</keyword>
  <keyword>Randomized clinical trial</keyword>
  <keyword>SNPs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

